[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343257-105":59,"doc-detail-343257-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-retrospective-analysis-suggests-pten-expression-is-associated-with-favorable-clinicopathological-features-of-breast-cancer-abstract-aim-and-objectives","A retrospective analysis suggests PTEN expression is associated with favorable clinicopathological features of breast cancer - Abstract, aim and objectives","","A retrospective analysis evaluates PTEN expression in breast cancer using 276 formalin-fixed paraffin-embedded (FFPE) tissue blocks collected from 2012 to 2016. Immunohistochemistry quantifies PTEN positivity and correlates results with tumor-related clinicopathological characteristics and patient demographics. Only 27.5% of tumors are PTEN-positive. PTEN expression shows significant associations with smaller tumor size, lower tumor grade, hormone receptor positivity, and favorable Ki-67 status (p\u003C0.001), while associations with vascular invasion, histologic type, age, HER2, staging, and lymph node involvement are not significant (p>0.05).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-retrospective-analysis-suggests-pten-expression-is-associated-with-favorable-clinicopathological-features-of-breast-cancer-abstract-aim-and-objectives/343257/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-retrospective-analysis-suggests-pten-expression-is-associated-with-favorable-clinicopathological-features-of-breast-cancer-abstract-aim-and-objectives/343257.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What study design and sample type were used to assess PTEN in breast cancer?","Question",{"text":113,"@type":114},"The study uses a retrospective analysis of 276 formalin-fixed paraffin-embedded (FFPE) breast cancer tissue blocks collected from 2012 to 2016. PTEN expression is measured with immunohistochemistry.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What proportion of breast cancer tumors showed PTEN positivity?",{"text":118,"@type":114},"Only 27.5% of the analyzed breast cancer tumors were PTEN-positive.",{"name":120,"@type":111,"acceptedAnswer":121},"Which clinical features were significantly associated with PTEN expression?",{"text":122,"@type":114},"PTEN expression correlated with smaller tumor size, lower tumor grade, positive estrogen and progesterone receptor status, and favorable/unfavorable Ki-67 status (p\u003C0.001). No significant associations were reported for vascular invasion, histologic type, age, HER2 status, staging, or lymph node involvement (p>0.05).","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343257,1790331275,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nA retrospective analysis suggests PTEN expression is associated with favorable clinicopathological features of breast cancer  \nLeonard Derkyi‑Kwarteng1, Frank Naku Ghartey2*, Eric Aidoo3, Ernest Addae1, Emmanuel Gustav Imbeah1, Ato Ampomah Brown 3 & Samuel Acquah4  \nThe phosphatase and tensin homolog (PTEN) gene acts as a tumor suppressor by regulating the PI3K/ AKT pathway, crucial for cell growth and survival. Mutations or loss of PTEN are common in breast cancer, leading to uncontrolled cell growth. Understanding PTEN’s role is vital for targeted therapies.  \n276 formalin‑fixed paraffin‑embedded (FFPE) breast cancer tissue blocks from 2012 to 2016 were analyzed for PTEN expression. Immunohistochemistry was performed to identify and assess tumor related clinicopathological characteristics as well as patient demographics. These were statistically matched with PTEN expression. Only 27.5% of the breast cancer tumors were PTEN‑positive. PTEN expression correlated significantly with smaller tumor size, lower tumor grade, positive estrogen and progesterone receptor status, and favorable/unfavorable Ki67 status (p \u003C 0.001) . No significant association was found with vascular invasion, histologic type, age, HER2 status, staging, or lymph node involvement (p > 0.05). The study confirms PTEN’s association with favorable clinicopathological features in breast cancer, supporting its role as a prognostic marker. These findings underscore the importance of PTEN in breast cancer biology and its potential as a therapeutic target. Furthermore these findings confirm the prevalence of advanced stage and aggressive breast cancer tumors in  \nGhana.  \nKeywords PTEN expression, Retrospective analysis, Clinicopathological characteristics, Breast carcinoma, Favorable prognosis, Archival samples  \nThe phosphatase and tensin homolog (PTEN) gene is a tumour suppressor gene located on chromosome 10q23 and has been found to be mutated in different cancers1. This protein has been shown to have a dual-specificity phosphatase with lipid and protein phosphatase activity which functions as a negative regulator of PI3K/AKToncogenic pathway. This is frequently mutated or deleted in human carcinogenesis. The antagonisation of the PI3K/AKT pathway is through the dephosphorylating PIP3, which results in decreased translocation of AKT to the cellular membrane.2–5.  \nThe activation of PTEN can be done through several different mechanisms including mutation, deletion, epigenetic silencing, transcriptional repression, microRNA regulation disruption of competitive endogenous RNA network, posttranslational modifications and aberrant PTEN localisation4,6,7.  \nThe PI3K/AKT is one of the potent signalling pathways promoted by HER 2 overexpression which affects cell cycle progression and inhibit apoptosis3. The heterodimer molecule, PI3K is composed of a regulatory subunit (p85) and a catalytic subunit (p110). When PI3K is activated by tyrosine kinase receptor, it phosphorylates PIP2 to produce PIP33,8.  \nThe PIP3 mobilises the serine/threonine kinase, AKT to the plasma membrane. With the phosphorylation of Ser 473 of AKT, several kinases are activated, which includes the mammalian target of rapamycin (mTOR), a molecule that regulates cell growth through p21 and p27, with other molecules that inhibit apoptosis such as Bad and caspase proteins3,9–11. The PI3K/Akt/mTOR pathway, found to be frequently overactive in human  \n1Department of Pathology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana. 2Department of Chemical Pathology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana. 3Department of Anatomy and Cell Biology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana. 4Department of Medical Biochemistry, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana. *email: [f.ghartey@uccsms.edu.gh](f.ghartey@uccsms.ed","cbCairtvauEx4coi","https://ap.wps.com/l/cbCairtvauEx4coi","pdf",1277964,"English","# Background\n## PTEN and PI3K/AKT pathway in cancer\n## PTEN roles in breast cancer\n# Study Aim\n# Study Objectives\n## Evaluate PTEN expression level\n## Assess clinicopathological characteristics","[{\"question\":\"What study design and sample type were used to assess PTEN in breast cancer?\",\"answer\":\"The study uses a retrospective analysis of 276 formalin-fixed paraffin-embedded (FFPE) breast cancer tissue blocks collected from 2012 to 2016. PTEN expression is measured with immunohistochemistry.\"},{\"question\":\"What proportion of breast cancer tumors showed PTEN positivity?\",\"answer\":\"Only 27.5% of the analyzed breast cancer tumors were PTEN-positive.\"},{\"question\":\"Which clinical features were significantly associated with PTEN expression?\",\"answer\":\"PTEN expression correlated with smaller tumor size, lower tumor grade, positive estrogen and progesterone receptor status, and favorable/unfavorable Ki-67 status (p\\u003c0.001). No significant associations were reported for vascular invasion, histologic type, age, HER2 status, staging, or lymph node involvement (p\\u003e0.05).\"}]","A retrospective analysis suggests PTEN expression is associated with favorable clinicopathological features of breast cancer - Abstract, aim and objectives | PDF",1790050471,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/168c95f7012c60896bd1324a8754b38b.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b527b40d083f054ed0430512be78f7c5.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6071e570ff80a1fb4d8ba0fcbc75b656.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c97fb30dccf4e1e59c0ecb149214b97.webp",980,1287]